STOCK TITAN

Kura Oncology (KURA) SEC Filings, Nov 10-17, 2026

KURA NASDAQ

Kura Oncology, Inc. filings document a Nasdaq-listed biopharmaceutical company focused on precision medicines for cancer, including disclosures on KOMZIFTI™ (ziftomenib), acute myeloid leukemia programs, darlifarnib (KO-2806) and collaboration activity with Kyowa Kirin. Form 8-K reports cover financial results, FDA approval and product-launch disclosures, clinical program updates, milestone payments and other material events.

Governance filings include the company’s definitive proxy statement for annual meeting matters, director elections, auditor ratification and executive compensation. Other filings describe amendments to bylaws, the 2023 Inducement Option Plan, nonstatutory stock option grants and the company’s common stock listing on The Nasdaq Global Select Market.

Rhea-AI Summary

Kura Oncology, Inc. officer Kathleen Ford reported a proposed sale of 3,668 common shares, with an approximate market value of $26,006.12 and an approximate sale date of November 17, 2026. Ford acquired the shares from the issuer as performance stock units on November 13, 2026.

During the prior three months, Ford reported sales of 7,042 shares for gross proceeds of $52,421.35 on November 16, 2026; 3,668 shares for $39,436.87 on September 29, 2026, listed as a 10b5-1 sale; and 6,906 shares for $72,494.35 on September 27, 2026. The reported Rule 10b5-1 plan adoption or instruction date is May 29, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.00%
Tags
other
-
Rhea-AI Summary

Kura Oncology, Inc. (KURA) President and CEO Troy Edward Wilson amended his insider report to classify purchases by the One Fish Two Fish Revocable Trust as indirect ownership. The trust bought 98,881 shares at a weighted average $7.63 per share on November 13, 2026, and 101,119 shares at a weighted average $7.42 per share on November 16. Afterward, Wilson reported 679,194 shares indirectly through the trust and 435,456 directly. The amendment says transaction details and aggregate beneficial ownership are unchanged.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.00%
Tags
insider
-
Rhea-AI Summary

Kura Oncology, Inc. (KURA) President and CEO Troy Edward Wilson reported two direct purchases of common stock: 98,881 shares at a weighted average price of $7.63 per share on November 13, 2026, and 101,119 shares at a weighted average price of $7.42 per share on November 16, 2026. The trades were executed in multiple transactions at $7.47–$7.79 and $7.27–$7.73, respectively. The reported holdings also include 479,194 shares held by the One Fish Two Fish Revocable Trust and 300,000 shares held by the Lorax Charitable Remainder Unitrust, with both entries dated November 13, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.64%
Tags
insider
Rhea-AI Summary

Kura Oncology, Inc. (KURA) officer Thomas James Doyle reported a planned sale of 4,697 shares of common stock, with an aggregate market value of $36,495.69 and an approximate sale date of November 16, 2026. The notice identifies the shares as acquired from the issuer on November 13, 2026, in a transaction designated “PSU.”

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.64%
Tags
other
-
Rhea-AI Summary

Kura Oncology, Inc. (KURA) reported that its officer Kathleen Ford plans to sell 7,042 shares of common stock, with an aggregate market value of $54,716.34, on approximately November 16, 2026. Ford acquired the shares from the issuer in a PSU transaction on November 13, 2026. The notice lists 92,784,785 common shares outstanding. It also reports two sales in the prior three months: 6,906 performance-based restricted stock units sold September 28, 2026, for gross proceeds of $72,494.35 in a sell-to-cover transaction, and 3,668 sold September 29, 2026, for gross proceeds of $39,436.71 in a 10b5-1 sale.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.64%
Tags
other
-
Rhea-AI Summary

Kura Oncology, Inc. (KURA) officer Brian Powl reported a proposed sale of 9,196 shares of common stock, with an aggregate market value of 71,452.92 and an approximate sale date of November 16, 2026. The shares were acquired from the issuer as restricted stock units on November 13, 2026. Morgan Stanley Smith Barney LLC is listed as broker. The notice also lists four sales in the prior three months.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.64%
Tags
other
Rhea-AI Summary

Kura Oncology, Inc. (KURA) officer Teresa Bair gave notice of a proposed sale of 8,601 common shares, with an approximate sale date of November 16, 2026 and an aggregate market value of $66,829.77. She acquired the shares from the issuer on November 13, 2026 as a PSU. The past-three-month sales table lists 8,442 performance-based restricted stock units sold September 28 in a sell-to-cover transaction for $88,618.21 in gross proceeds, and 31,487 restricted stock units in an August 19 entry labeled 10b5-1 Sales, with $397,829.73 in gross proceeds.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.64%
Tags
other
-
Rhea-AI Summary

Kura Oncology, Inc. (KURA) lists a Form 144 notice by officer Mollie Leoni for a proposed sale of 19,009 common shares, with an aggregate market value of $147,699.93 and an approximate sale date of November 16, 2026. The shares are listed as acquired from the issuer through a PSU transaction on November 13, 2026.

During the preceding three months, the notice lists a sell-to-cover sale of 12,448 performance-based restricted stock units on September 28, 2026, for gross proceeds of $130,670.39, and 28,802 units in an entry labeled 10b5-1 Sales on September 29, 2026, for gross proceeds of $309,565.84. The listed number of common shares outstanding is 92,784,785. Teresa Bair signed as attorney-in-fact for Mollie Leoni.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.64%
Tags
other
-
Rhea-AI Summary

Kura Oncology, Inc. (KURA) is the issuer whose common stock is covered by an amended beneficial-ownership report from several BVF-related reporting persons. As of September 30, 2026, Biotechnology Value Fund, L.P. reported 3,499,795 shares (3.9%), Biotechnology Value Fund II, L.P. reported 2,621,048 shares (2.9%), and Biotechnology Value Trading Fund OS LP reported 443,395 shares (0.5%). BVF GP Holdings LLC was attributed 6,120,843 shares (6.9%); BVF Partners L.P., BVF Inc. and Mark N. Lampert, a director and officer of BVF Inc., were each attributed 6,690,108 shares (7.5%).

The report describes shared voting and dispositive power and related-party relationships. It says deemed ownership by one reporting person is not itself an admission of ownership of shares held by another, and includes specific beneficial-ownership disclaimers from related entities and Mr. Lampert. The percentages use 88,960,619 shares outstanding as of August 7, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.64%
Tags
ownership
Rhea-AI Summary

Kura Oncology, Inc. may offer common stock with an aggregate offering price of up to $150.0 million from time to time through Leerink Partners LLC and Cantor Fitzgerald & Co. as sales agents in at-the-market offerings. The agents are not required to sell a specified amount, and their compensation may be up to 3.0% of gross proceeds from shares sold. Kura intends to use net proceeds to support KOMZIFTI commercialization, advance its pipeline, and fund working capital and other general corporate purposes. In a dilution illustration, an assumed sale of 19,815,059 shares at $7.57 per share results in estimated immediate dilution of $6.10 per share. The illustration shows adjusted net tangible book value of approximately $164.7 million, or $1.47 per share, after the assumed sale.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.11%
Tags
other

FAQ

How many Kura Oncology (KURA) SEC filings are available on StockTitan?

StockTitan tracks 130 SEC filings for Kura Oncology (KURA), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Kura Oncology (KURA)?

The most recent SEC filing for Kura Oncology (KURA) was filed on November 19, 2026.